Literature DB >> 19348967

Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency.

Ji Hua Guo1, Ming Wen Fan, Jing Hua Sun, Rong Jia.   

Abstract

DNA vaccination is a promising method to induce specific immune responses. However, it remains challenging to enhance DNA vaccine potency. Chemokines were used as adjuvants to improve the efficacy of DNA vaccination. Herein, we fused murine chemokine CCL20 or CXCL13 to a model antigen green fluorescent protein (GFP). The fusion DNA vaccines enhanced specific anti-GFP immune responses in mice compared with vector pEGFP-N1. Co-immunization with both of chemokine-GFP fusion constructs induced the significantly highest level of humoral immune responses. CCL20-GFP or CXCL13-GFP fusion DNA vaccine induced predominant IgG2a or IgG1 response respectively. However, co-immunization with both of these fusion DNA vaccines induced a predominant IgG2a response. Therefore, fusing chemokine CXCL13 or CCL20 to antigen provides new attractive strategy to enhance the immunogenicity of DNA vaccine and modulate immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19348967     DOI: 10.1016/j.intimp.2009.03.019

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells.

Authors:  Zhao Wang; Mingming Li; Ming Zhou; Yajing Zhang; Jie Yang; Yandi Cao; Kunlun Wang; Min Cui; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

2.  Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.

Authors:  A N Meleshko; N A Petrovskaya; N Savelyeva; K P Vashkevich; S N Doronina; N V Sachivko
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

3.  Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency.

Authors:  Xinmei Xie; Lin Wang; Wenliang Yang; Ruishuang Yu; Qingli Li; Xiaobin Pang
Journal:  Invest New Drugs       Date:  2015-05-09       Impact factor: 3.850

4.  Functional characterization of ferret CCL20 and CCR6 and identification of chemotactic inhibitors.

Authors:  Shulin Qin; Cynthia R Klamar; Beth A Fallert Junecko; Jodi Craigo; Deborah H Fuller; Todd A Reinhart
Journal:  Cytokine       Date:  2013-01-27       Impact factor: 3.861

5.  Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.

Authors:  James T Gordy; Kun Luo; Hong Zhang; Arya Biragyn; Richard B Markham
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

6.  Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate.

Authors:  Ju-Ri Sim; Seok-Seong Kang; Daesang Lee; Cheol-Heui Yun; Seung Hyun Han
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

7.  Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant.

Authors:  Christine Hartoonian; Zargham Sepehrizadeh; Mehdi Mahdavi; Arash Arashkia; Yon Suk Jang; Maasoumeh Ebtekar; Mojtaba Tabatabai Yazdi; Babak Negahdari; Azita Nikoo; Kayhan Azadmanesh
Journal:  Mol Biol Rep       Date:  2014-06-28       Impact factor: 2.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.